Maria Camila Espinal, MD | |
6355 Walker Ln Ste 401, Alexandria, VA 22310-3250 | |
(703) 924-2100 | |
(703) 922-6067 |
Full Name | Maria Camila Espinal |
---|---|
Gender | Female |
Speciality | Student In An Organized Health Care Education/training Program |
Location | 6355 Walker Ln Ste 401, Alexandria, Virginia |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1306423801 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208000000X | Pediatrics | 0101281692 (Virginia) | Secondary |
390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Maria Camila Espinal, MD 625 Monroe St Ne Apt 331, Washington, DC 20017-1781 Ph: (305) 807-9013 | Maria Camila Espinal, MD 6355 Walker Ln Ste 401, Alexandria, VA 22310-3250 Ph: (703) 924-2100 |
News Archive
Take Care Health Systems is now offering nebulizer treatments, when clinically appropriate, for clinic patients exhibiting acute respiratory distress.
San Francisco and Berkeley missed an opportunity to help smokers quit when the cities moved all tobacco sales out of pharmacies, according to a new Bay Area health initiative. Instead of having smokers buy cigarettes in convenience stores and at other retailers, smokers should buy cigarettes only at pharmacy counters, says Stuart Skorman, founder of Elephant Pharmacy.
Cypher Genomics, Inc., the genome informatics company, announced today the identification of de novo KCNB1 missense mutations as a novel genetic cause of severe epileptic encephalopathy. Cypher's co-founder and Chief Scientific Officer Ali Torkamani, Ph.D. reviewed the data today at a platform presentation at the ASHG 2014 meeting being held October 18 to 22 in San Diego.
Data from interim analyses of a Phase III clinical study in patients with primary immune deficiency (PID) who received Baxter's HyQ were presented at the 26th meeting of the European Society for Immunodeficiencies (ESID) in Istanbul, Turkey. HyQ is an immune globulin (IG) therapy facilitated subcutaneously by recombinant human hyaluronidase, a dispersion and permeation enhancer.
› Verified 4 days ago